Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

DiaMedica Therapeutics (DMAC) Receivables (2017 - 2026)

DiaMedica Therapeutics filings provide 10 years of Receivables readings, the most recent being $586000.0 for Q1 2026.

  • Quarterly Receivables rose 21.58% to $586000.0 in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $586000.0 through Mar 2026, up 21.58% year-over-year, with the annual reading at $508000.0 for FY2025, 114.35% up from the prior year.
  • Receivables hit $586000.0 in Q1 2026 for DiaMedica Therapeutics, up from $508000.0 in the prior quarter.
  • Across five years, Receivables topped out at $790000.0 in Q1 2024 and bottomed at $75000.0 in Q3 2022.
  • Average Receivables over 5 years is $394823.5, with a median of $440000.0 recorded in 2023.
  • The largest annual shift saw Receivables crashed 72.84% in 2022 before it skyrocketed 725.33% in 2023.
  • DiaMedica Therapeutics' Receivables stood at $84000.0 in 2022, then soared by 423.81% to $440000.0 in 2023, then crashed by 46.14% to $237000.0 in 2024, then skyrocketed by 114.35% to $508000.0 in 2025, then grew by 15.35% to $586000.0 in 2026.
  • Per Business Quant, the three most recent readings for DMAC's Receivables are $586000.0 (Q1 2026), $508000.0 (Q4 2025), and $488000.0 (Q3 2025).